CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia

• Status: NOT_YET_RECRUITING
• Trial end date: 2028-12-01

Summary

To assess the efficacy of administrating daily caspofungin aerosols versus placebo for seven days, in adjunction of conventional systemic antifungal therapy during curative treatment of Pneumocystis pneumonia, on the clinical outcome at the end of the nebulized therapy, in order to support a "GO / NO GO" decision towards a phase III trial of nebulized caspofungin in those patients.

• Phase: PHASE1

Details

• Lead Sponsor: University Hospital, Tours
• Collaborators: Aerogen; Amiens University Hospital; Cape Cod Incorporated; Centre Hospitalier Universitaire de Besancon; Centre Hospitalier Universitaire de Nice; Centre Hospitalier Universitaire Dijon; Henri Mondor University Hospital; Hopital Foch; Hospices Civils de Lyon; Hospital Avicenne; Hpital Necker-Enfants Malades; Institut National de la Sant Et de la Recherche Mdicale, France; Nantes University Hospital; Ohre Pharma; Piti-Salptrire Hospital; Poitiers University Hospital; Reims University hospital; Rennes University Hospital; Tours university; University Hospital, Angers; University Hospital, Bordeaux; University Hospital, Brest; University Hospital, Grenoble; University Hospital, Lille; University Hospital, Limoges; University Hospital, Montpellier; Wako Diagnostics
• Treatments: Caspofungin